Physiologic Changes During Pregnancy and Impact on Small-Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response

被引:19
作者
Eke, Ahizechukwu C. C. [1 ,5 ]
Gebreyohannes, Rahel D. D. [2 ]
Fernandes, Maria Fernanda Scantamburlo [3 ]
Pillai, Venkateswaran C. C. [4 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Div Maternal Fetal Med, Baltimore, MD 21287 USA
[2] Addis Ababa Univ, Coll Med, Dept Obstet & Gynecol, Addis Ababa, Ethiopia
[3] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN USA
[4] US FDA, Silver Spring, MD USA
[5] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Div Maternal Fetal Med & Clin Pharmacol, 600 N Wolfe St, Baltimore, MD 21287 USA
基金
美国国家卫生研究院;
关键词
biologics; monoclonal antibodies; physiology; pharmacodynamics; pharmacokinetics; pregnancy; NEONATAL FC-RECEPTOR; CLINICAL PHARMACOKINETICS; NIFEDIPINE PHARMACOKINETICS; POPULATION PHARMACOKINETICS; 3RD TRIMESTER; PLASMA; WOMEN; PHARMACODYNAMICS; METABOLISM; THERAPY;
D O I
10.1002/jcph.2227
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pregnancy is a unique physiological state that results in many changes in bodily function, including cellular, metabolic, and hormonal changes. These changes can have a significant impact on the way small-molecule drugs and monoclonal antibodies (biologics) function and are metabolized, including efficacy, safety, potency, and adverse effects. In this article, we review the various physiologic changes that occur during pregnancy and their effects on drug and biologic metabolism, including changes in the coagulation, gastrointestinal, renal, endocrine, hepatic, respiratory, and cardiovascular systems. Additionally, we discuss how these changes can affect the processes of drug and biologic absorption, distribution, metabolism, and elimination (pharmacokinetics), and how drugs and biologics interact with biological systems, including mechanisms of drug action and effect (pharmacodynamics) during pregnancy, as well as the potential for drug-induced toxicity and adverse effects in the mother and developing fetus. The article also examines the implications of these changes for the use of drugs and biologics during pregnancy, including consequences of suboptimal plasma drug concentrations, effect of pregnancy on the pharmacokinetics and pharmacodynamics of biologics, and the need for careful monitoring and individualized drug dosing. Overall, this article aims to provide a comprehensive understanding of the physiologic changes during pregnancy and their effects on drug and biologic metabolism to improve the safe and effective use of drugs.
引用
收藏
页码:S34 / S50
页数:17
相关论文
共 130 条
[1]   Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies [J].
Albitar, M ;
Do, KA ;
Johnson, MM ;
Giles, FJ ;
Jilani, I ;
O'Brien, S ;
Cortes, J ;
Thomas, D ;
Rassenti, LZ ;
Kipps, TJ ;
Kantarjian, HM ;
Keating, M .
CANCER, 2004, 101 (05) :999-1008
[2]   Chronic Hypertension in Pregnancy mas [J].
Vidaeff, Alex ;
Espinoza, Jimmy ;
Simhan, Hyagriv ;
Pettker, Christian M. .
OBSTETRICS AND GYNECOLOGY, 2019, 133 (01) :E26-E50
[3]   Effect of Pregnancy on the Pharmacokinetics of Antihypertensive Drugs [J].
Anderson, Gail D. ;
Carr, Darcy B. .
CLINICAL PHARMACOKINETICS, 2009, 48 (03) :159-168
[4]   Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach [J].
Anderson, GD .
CLINICAL PHARMACOKINETICS, 2005, 44 (10) :989-1008
[5]   Amoxicillin pharmacokinetics in pregnant women: Modeling and simulations of dosage strategies [J].
Andrew, M. A. ;
Easterling, T. R. ;
Carr, D. B. ;
Shen, D. ;
Buchanan, M. L. ;
Rutherford, T. ;
Bennett, R. ;
Vicini, P. ;
Hebert, M. F. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :547-556
[6]   Pharmacokinetics and Pharmacodynamics of Drugs Commonly Used in Pregnancy and Parturition [J].
Ansari, Jessica ;
Carvalho, Brendan ;
Shafer, Steven L. ;
Flood, Pamela .
ANESTHESIA AND ANALGESIA, 2016, 122 (03) :786-804
[7]   Virchow and his triad: a question of attribution [J].
Bagot, Catherine N. ;
Arya, Roopen .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (02) :180-190
[8]   A prospective triat that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levets of anticoagulation [J].
Barbour, LA ;
Oja, JL ;
Schultz, LK .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (03) :1024-1029
[9]   NIFEDIPINE PHARMACOKINETICS AND PHARMACODYNAMICS DURING THE IMMEDIATE POSTPARTUM PERIOD IN PATIENTS WITH PREECLAMPSIA [J].
BARTON, JR ;
PREVOST, RR ;
WILSON, DA ;
WHYBREW, WD ;
SIBAI, BM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 165 (04) :951-954
[10]   Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy [J].
Bastian, Jaime R. ;
Chen, Huijun ;
Zhang, Hongfei ;
Rothenberger, Scott ;
Tarter, Ralph ;
English, Dennis ;
Venkataramanan, Raman ;
Caritis, Steve N. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 216 (01)